-
Bolus Insulin (Prandial)
- Rapid-Acting Insulin
- Short-Acting Insulin
-
Rapid-Acting Insulin
- -For small eater
- Brand/Generic:
- NovoLOG/Insulin aspart
- Apidra/Insulin glulisine
- HumaLOG/Insulin lispro
- Onset: 15min (Given while plate is hot)
- Peak: 30-90min
- Duration: 3-5hr
-
Short-Acting Insulin
- -For large eater
- Generic: Regular
- Brand:
- Humulin R
- Novolin R
- Onset: 30-60min (Given 30 mins before eating)
- Peak: 2-4hr (Check BS 2hrs, give more prn; watch out for hypoglycemia s/s- shakes and sweats)
- Duration: 5-8hr
-
Basal Insulin (continuous)
- Intermediate-acting
- Long-acting
-
Intermediate Acting Insulin
- -Common Basal Insulin
- Generic: NPH
- Brand:
- Humulin N
- Novolin N
- Onset: 1-3hrs
- Peak: 8hrs (Given 2x: Am & PM; or as ordered)
- Duration: 12-16hrs
-
Long-acting Insulin
- -Expensive = as afforded
- Brand/Generic:
- Levemir/Insulin determir
- Lantus/Insulin glargine
- Onset: 1hr
- Peak: Peak-less!!!
- Duration: 20-26hrs (1qday)
-
Basal/Bolus Mix
- Pre-mixed NPH (intermediate) & Regular (short)
- Pre-mixed insulin lispro protamine suspenion (intermediate) & insulin lispro (rapid)
- Pre-mixed insulin aspart protamine suspension (intermediate) & insulin aspart (rapid)
-
Pre-mixed NPH (intermediate) & Regular (short)
- Brand/Generic:
- Humilin(70/30) = 70% NPH & 30% Regular
- Novolin(30/30) = "~~~~~~~~~~~~~~~~~"
- Humulin (50/50) = 50% NPH & 50% Regular
- Onset: 30-60min
- Peak: varies
- Duration: 10-16hr
-
Pre-mixed insulin lispro protamine suspenion (intermediate) & insulin lispro (rapid)
- Brand/Generic:
- HumaLog Mix (75/25) = 75% insulin lispro protamine & 25% insulin lispro
- HumaLog Mix (50/50) = 50% "~~~~" & 50% "~~"
- Onset: 10-15min
- Peak: varies
- Duration: 10-16hrs
-
Pre-mixed insulin aspart protamine suspension (intermediate) & insulin aspart (rapid)
- Brand/Generic:
- NovoLog Mix (70/30) = 70% Insulin aspart protamine & 30% insulin aspart
- Onset: 5-15min
- Peak: varies
- Duration: 10-16hrs
-
Fasting Blood Glucose (FBG) test
- Normal range: <100 mg/dL [rises as age]
- Impaired fasting glucose (IFG): <126 mg/dL
- Procedure: Casual/Random Glucose check
- Every: AC&HS (4qday)
- Equipment: Acu-check
- (Fasting defines as no caloric intake at least 8hrs)
- (Casual as anytime w/o regard on time since last meal)
- S/S diabetes: polyuria, polydipsia, unexplained weight loss
-
(Oral) Glucose Tolerance Test (OGTT)
- Normal: <140 mg/dL
- Impaired glucose tolerance (IGT): <200 mg/dL
- Procedure: NPO 8-12hr prior test, drink high glucose (75grams glucose in water), blood test 2hrs late, if result is high glucose level = potential diabetes
-
Glycosylated hemoglobin (A1C) test (HbA1C)
- Normal: 4-6%
- Risk diabetes: 5.7-6.4%
- Poor diabetes control: >8%
- Procedure: Measures the amount of glycosylated hemoglobin (hemoglobin that is chemically linked to glucose) in blood. >6.5% = lab test using NGSP certified & standardized to DCCI assay
- Check every: 3 mos.
- A1C% - mg/dL - mmo/L
- 6 - 126 - 7
- 7 - 154 - 8.6
- 8 - 183 - 10.2
- 9 - 212 - 11.8
- 10 - 240 - 13.4
- 11 - 269 - 14.9
- 12 - 298 - 16.5
-
Secretagogus
- Lower fasting plasma (blood) glucose lvl by triggering release of insulin from beta cells
- 2nd-Gen Sulfonylurea Agents
- Glipizide (Glucotrol)
- Glimepiride (Amaryl)
-
Glipizide (Glucotrol)
- Secretagogus: Lower fasting plasma (blood) glucose lvl by triggering release of insulin from beta cells
- 2nd-Gen Sulfonylurea Agents
- Route: Oral
- S/E: hypoglycemia, weight gain, interacts w/ many drugs
-
Glimepiride (Amaryl)
- Secretagogus: Lower fasting plasma (blood) glucose lvl by triggering release of insulin from beta cells
- 2nd-Gen Sulfonylurea Agents
- Route: oral
- S/E: hypoglycemia
-
Meglitinide Analogs
- Lower fasting plasma (blood) glucose lvl by triggering release of insulin from beta cells
- Repaglinide (Prandin)
- Nateglinide (Starlix)
- Biguinides: Metaformin (Glucophage)****
-
Repaglinide (Prandin)
- Meglitinide Analogs:Lower fasting plasma (blood) glucose lvl by triggering release of insulin from beta cells
- Route: Oral
- S/E: Hypoglycemia
-
Nateglinide (Starlix)
- Meglitinide Analogs:Lower fasting plasma (blood) glucose lvl by triggering release of insulin from beta cells
- Route: Oral
- S/E: Hypoglycemia
-
Biguinides: Metaformin (Glucophage)****
- Meglitinide Analogs:Lower fasting plasma (blood) glucose lvl by triggering release of insulin from beta cells
- Route: Oral
- S/E: Abd discomfort (diarrhea, nausea, vomit, flatulence, indigestion), lactic acidosis, interact w/ contrast material & can induce acute kidney injury
-
Insulin Sensitizers
- Don't increase insulin secretion. Decrease liver glucose production, reducing fasting plasma (blood) glucose release, & improve insulin receptors sensitivity. TDZs also increase cellular utilization of glucose.
- Thiazolidinediones (TZDs):
- Pioglitazone (Actos)
- Rosiglitazone (Avandia)
-
Pioglitazone (Actos): a Thiazolidinediones (TZDs)
- Insulin Sensitizers: Don't increase insulin secretion. Decrease liver glucose production, reducing fasting plasma (blood) glucose release, & improve insulin receptors sensitivity. TDZs also increase cellular utilization of glucose.
- Route: Oral
- S/E + risk for:
- Heart-related death; not to be used by pt w/ symptomatic heart failure
- bone fracture & macular edema
- liver impairment
- bladder cancer
-
Rosiglitazone (Avandia): a Thiazolidinediones (TZDs)
- Insulin Sensitizers: Don't increase insulin secretion. Decrease liver glucose production, reducing fasting plasma (blood) glucose release, & improve insulin receptors sensitivity. TDZs also increase cellular utilization of glucose.
- Route: Oral
- S/E + risk for:
- Heart-related death; not to be used by pt w/ symptomatic heart failure
- bone fracture & macular edema
- liver impairment
-
Alpha-Glucosidase Inhibitors
- Prevent after-meal hyperglycemia by inhibiting enzymes in intestinal tract, reducing rate of digestion of starches, & delaying absorption of carbohydrate from small intestine
- Acarbose (Precose)
- Miglitose (Glyset)
-
Acarbose (Precose)
- Alpha-Glucosidase Inhibitors: Prevent after-meal hyperglycemia by inhibiting enzymes in intestinal tract, reducing rate of digestion of starches, & delaying absorption of carbohydrate from small intestine
- Route: Oral
- S/E:
- abd discomfort (diarrhea, nausea, vomit, flatulence, bloating, indigestion)
- elevates serum transaminase lvl & reduce liver function
- drug accumulates in pt w/ kidney impairment
-
Miglitose (Glyset)
- Alpha-Glucosidase Inhibitors: Prevent after-meal hyperglycemia by inhibiting enzymes in intestinal tract, reducing rate of digestion of starches, & delaying absorption of carbohydrate from small intestine
- Route: Oral
- S/E:
- abd discomfort (diarrhea, nausea, vomit, flatulence, bloating, indigestion)
- elevates serum transaminase lvl & reduce liver function
- drug accumulates in pt w/ kidney impairment
-
Incretin Mimetics (GLP-1 agonists)
- Acts like natural "gut" hormones that work w/ insulin to lower plasma (blood) glucose lvl. They lower glucagon secretion from pancreas = reduced liver glucose production. Also reduce blood glucose lvl by delaying gastric emptying, slowing rate of nutrient absorption into blood, & reducing food intake.
- Albiglutide (Tanzeum)
- Exenatide (Byetta)****
- Exentide extended release (Bydureon)
- Liraglutide (Victoza)
-
Albiglutide (Tanzeum)
- Incretin Mimetics (GLP-1 agonists): Acts like natural "gut" hormones that work w/ insulin to lower plasma (blood) glucose lvl. They lower glucagon secretion from pancreas = reduced liver glucose production. Also reduce blood glucose lvl by delaying gastric emptying, slowing rate of nutrient absorption into blood, & reducing food intake.
- Route: SQ injection (1qweek)
- S/E + risk:
- pancreatitis
- thyroid cancer
-
Exenatide (Byetta)***
- Incretin Mimetics (GLP-1 agonists): Acts like natural "gut" hormones that work w/ insulin to lower plasma (blood) glucose lvl. They lower glucagon secretion from pancreas = reduced liver glucose production. Also reduce blood glucose lvl by delaying gastric emptying, slowing rate of nutrient absorption into blood, & reducing food intake.
- Route: SQ injection
- S/E + risk:
- pancreatitis
- hypersensitivity reactions, including Steven-Johnson syndrome
-
Exentide extended release (Bydureon)
- Incretin Mimetics (GLP-1 agonists): Acts like natural "gut" hormones that work w/ insulin to lower plasma (blood) glucose lvl. They lower glucagon secretion from pancreas = reduced liver glucose production. Also reduce blood glucose lvl by delaying gastric emptying, slowing rate of nutrient absorption into blood, & reducing food intake.
- Route: SQ injection (1qweek)
- S/E + risk:
- pancreatitis
- thyroid cancer
-
Liraglutide (Victoza)
- Incretin Mimetics (GLP-1 agonists): Acts like natural "gut" hormones that work w/ insulin to lower plasma (blood) glucose lvl. They lower glucagon secretion from pancreas = reduced liver glucose production. Also reduce blood glucose lvl by delaying gastric emptying, slowing rate of nutrient absorption into blood, & reducing food intake.
- Route: SQ injection (1qweek)
- S/E + risk:
- pancreatitis
- thyroid cancer
-
DPP-4 Inhibitors
- DPP-4 is an enzyme that breaks down natural gut hormones (GLP-1 & GIP). DPP-4 inhibitors + amount of natural substances that work w/ insulin to lower glucagon secretion form pancreas = reduced liver glucose production. Also reduce blood glucose levels by delaying gastric emptying, slowing rate of nutrient absorption into blood, & reducing food intake.
- Sitagliptin (Januvia)***
- Saxagliptin (Onglyza)
- Linagliptin (Tradjenta)
- Alogliptinn (Nesina)
-
Sitagliptin (Januvia)***
- DPP-4 Inhibitors: DPP-4 is an enzyme that breaks down natural gut hormones (GLP-1 & GIP). DPP-4 inhibitors + amount of natural substances that work w/ insulin to lower glucagon secretion form pancreas = reduced liver glucose production. Also reduce blood glucose levels by delaying gastric emptying, slowing rate of nutrient absorption into blood, & reducing food intake.
- Route: Oral
- S/E + risk for: pancreatitis
-
Saxagliptin (Onglyza)
- DPP-4 Inhibitors: DPP-4 is an enzyme that breaks down natural gut hormones (GLP-1 & GIP). DPP-4 inhibitors + amount of natural substances that work w/ insulin to lower glucagon secretion form pancreas = reduced liver glucose production. Also reduce blood glucose levels by delaying gastric emptying, slowing rate of nutrient absorption into blood, & reducing food intake.
- Route: Oral
- S/E + risk for: pancreatitis
-
Linagliptin (Tradjenta)
- DPP-4 Inhibitors: DPP-4 is an enzyme that breaks down natural gut hormones (GLP-1 & GIP). DPP-4 inhibitors + amount of natural substances that work w/ insulin to lower glucagon secretion form pancreas = reduced liver glucose production. Also reduce blood glucose levels by delaying gastric emptying, slowing rate of nutrient absorption into blood, & reducing food intake.
- Route: Oral
- S/E + risk for: pancreatitis
-
Alogliptinn (Nesina)
- DPP-4 Inhibitors: DPP-4 is an enzyme that breaks down natural gut hormones (GLP-1 & GIP). DPP-4 inhibitors + amount of natural substances that work w/ insulin to lower glucagon secretion form pancreas = reduced liver glucose production. Also reduce blood glucose levels by delaying gastric emptying, slowing rate of nutrient absorption into blood, & reducing food intake.
- Route: Oral
- S/E + risk for:
- pancreatitis
- Kazano (alogliptin/metaformin combination) carries black box warning for lactic acidosis)
-
Amylin Analogs
- Similar to amylin, a naturally occurring hormone produced by beta cells in pancreas that is co-secreted w/ insulin & lowers blood glucose lvl by delaying gastric emptying & triggering satiety
- Pramlintide (Symlin)***
-
Pramlintide (Symlin)***
- Amylin Analogs: Similar to amylin, a naturally occurring hormone produced by beta cells in pancreas that is co-secreted w/ insulin & lowers blood glucose lvl by delaying gastric emptying & triggering satiety
- Route: SQ injections
- S/E:
- severe hypoglycemia
- nausea & vomiting
-
Fixed combinations
- There are many fixed combo of oral drug available
- S/E of combo drugs are same as for each component of combo
- When drug has s/e of hypoglycemia is combined w/ drug that does not alone produce hypoglycemia, development of hypoglycemia is still very much a risk for combo agents
-
Carbs
- Responsible for postmeal glucose
- Recommend: 45% calorie from carb/ 130g carb qday
-
Dietary Fat/Cholesterol
- Same as reduce risk for cardiovascular disease
- Fat quality is more important in lipid control than fat quantity
- Recommend:
- Limit fat intake 20-35% of daily cal intake
- Choose mono-unsaturated & poly-unsaturated fats (vs saturated fats & trans fats)
- Have 2+ servings of fatty fish qweek (except commercial fried fish) to provide n-3 poly-unsaturated fatty acids
- Trans fat: + risk cardiovascular disease (margarine, fried)
-
Protein
- Recommend: 15-20% of total diet calories
- Some higher % to substitute from carbohydrates, to maintain satiety & control blood glucose lvl
- High protein improve insulin response, but doesn't prevent hypoglycemia
-
Fiber
- Improves carbohydrate metabolism & lowers cholesterol levels
- Recommend: 25g women, 38g men.
-
Sucrose, Fructose, non-nutritive sweeteners (NNS)
- Sucrose: doesn't + blood glucose more than equal amounts of other starches
- Intake of sucrose & sucrose-containing food by DM pt doesn't need to be restricted out of concern for causing hyperglycemia
- Sucrose can be in meal as long as adequately covered w/ insulin or other glucose lowering agents
- Avoid: sugar sweetened beverages (SSBs); high-fructose corn syrup (+ triglycerides & other lipids)
- NNS: desirable since it doesn't disturb blood glucose control
- Free fructose: found in fruit doesn't appear to alter lipid metabolism like high-fructose corn syrup does
-
Alcohol
- Affects blood glucose, but not by moderate use
- Raises blood triglycerides
- Potential for alcohol-hypoglycemia, instruct pt w/ DM to ingest alcohol only w/ or shortly after meals
-
Retinopathy
- Avoid:
- Vigorous or resistance exercise
- Valsalva maneuver: Breath holding while bearing down
|
|